Robert W. Harrison, MD; Richard C. Becker, MD; Thomas L. Ortel, MD, PhD; Maragatha Kuchibhatla, PhD; Stephen H. Boyle, PhD; Zainab Samad, MD; Eric J. Velazquez,

Slides:

Advertisements

Similar presentations

Current Quality of Cardiovascular Prevention for Million Hearts™ An Analysis of 147,038 Outpatients from The Guideline Advantage ™ Zubin J. Eapen, MD,

Advertisements

Connie N. Hess, MD, Bimal R. Shah, MD, MBA, S. Andrew Peng, MS, Laine Thomas, PhD, Matthew T. Roe, MD, MHS, Eric D. Peterson, MD, MPH Relationship of Early.

Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: a Report from TRANSLATE-ACS Connie N. Hess, MD 1 ; Tracy Y. Wang, MD,

PubMed was searched for randomized clinical trials published between 2007 and 2012 in the New England Journal of Medicine (NEJM) Trials were included if.

A Noninvasive, Hand-Held Device for Assessing Left Ventricular End-Diastolic Pressure Based on Finger Photoplethysmography and the Valsalva Maneuver Panagis.

On behalf of the TRILOGY ACS Investigators Prasugrel versus clopidogrel for patients with unstable angina/non-ST-segment elevation myocardial infarction.

Clinical Trials. Date & location – January-November 1998, stress SPECT patients randomly received tetrofosmin or sestamibi (n~1550) Inclusion criteria.

CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.

RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.

Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) Echocardiographic.

Effect of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy versus ARB plus Calcium Channel Blocker Combination on Cardiovascular Events in Japanese.

Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD.

1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Patients with HF have increased risk for thrombotic events. However, the net clinical benefit of anticoagulation in a HF population in sinus rhythm has.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.

PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.

1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.

How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,

The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,

Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,

High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.

Silent Ischemia STABLE CAD

Clinical Trial Results. org Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease:

Managing Patients Who Cannot Take Anticoagulants Kenneth W. Mahaffey, MD, FACC Professor of Medicine, Cardiology Faculty Associate Director, DCRI Director,

Effect of the Renin Inhibitor Aliskiren on Progression of Coronary Atherosclerosis: AQUARIUS Study Results SJ Nicholls, GL Bakris, JJP Kastelein, V Menon,

Endothelial Function and Vascular Response to Mental Stress are Impaired in Patients with Apical Ballooning Syndrome Elizabeth A. Martin, PhD; Abhiram.

Hideki Shimomura, MD* 1 ; Seiji Hokimoto, MD* 2 ; Shuichi Oshima, MD* 3 ; Koichi Nakao, MD* 4 ; Yuji Miyao, MD* 5 ; Hisao Ogawa, MD* 2 ; for the Kumamoto.

Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.

6/9/2008 Comparative effectiveness reviews: methodological observations David B. Matchar, MD Professor of Medicine and Director, Center for Clinical Health.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Trends in the Quality of Care of Patients with Acute Myocardial Infarction: The National Registry of Myocardial Infarction from 1990 to 2006 Bimal R. Shah,

All Rights Reserved, Duke Medicine 2008 Mechanical Dyssynchrony Defined by Phase Analysis from GSPECT: Does It Predict Mortality? Paul L. Hess, MD; Linda.

Can we better protect patients who undergo revascularization? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing.

Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.

PROTECT: What Have We Learned Lesson 2: TMPG is associated with clinical and biomarker outcomes following PCI.

Prospective Randomized Comparison of Conventional Stress Echocardiography with Real Time Perfusion Stress Echocardiography in Predicting Clinical Outcome.

Major Bleeding is Associated with Increased One-Year Mortality and Ischemic Events in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary.

Insights from the PROMISE Trial Neha J. Pagidipati, MD MPH; Kshipra Hemal; Adrian Coles, PhD; Daniel B. Mark, MD MPH; Rowena J. Dolor, MD MHS; Patricia.

Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Psychological Stress and Cardiovascular Disease J.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Prognostic Value of B-Type Natriuretic Peptides in Patients with Stable Coronary Artery Disease The PEACE trial Omland T, et al. JACC 2007;50:

A Clinical and Echocardiographic Score for Assigning Risk of Major Events After Dobutamine Echocardiograms JACC Vol. 43, No June 2, 2004:2102–7.

Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology The EXERRT trial – “EXErcise to Regadenoson in Recovery.

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.

The RAdial SAme Day DischArge after PCI The RASADDA-PCI trial

Total Occlusion Study of Canada (TOSCA-2) Trial

Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:

Revascularization in Patients With Left Ventricular Dysfunction:

Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital.

Racial Differences in the Association between Clinical Measures and Self-Reported Health Status in Bypass Angioplasty Revascularization Investigation.

Influence of Afterload on Global and Basal Longitudinal Strain: Comparison of Blood Pressure and Wall Stress Upasana Jarori, M. Waqas Choudhry, Shujaur.

Pathways in Anticoagulation

The ANTARCTIC investigators

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Prevalence of statin and beta-blocker use by clinical presentation

The Impact of Different Treatment Strategies on Cardiac Death and MI Rates in Patients with Type 2 Diabetes and Stable Coronary Disease: A Report from.

The Impact of Different Treatment Strategies on Cardiac Death and MI Rates in Patients with Type 2 Diabetes and Stable Coronary Disease: A Report from.

Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.

Financial Disclosures

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Update on the New Antiplatelet Agents:

β-Blocker Use for the Stages of Heart Failure

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Presentation transcript:

Robert W. Harrison, MD; Richard C. Becker, MD; Thomas L. Ortel, MD, PhD; Maragatha Kuchibhatla, PhD; Stephen H. Boyle, PhD; Zainab Samad, MD; Eric J. Velazquez, MD; Jennifer Wilson, BA; Cynthia Kuhn, PhD; Redford B. Williams, MD; Christopher M. O’Connor, MD; Wei Jiang, MD Duke University, Durham, NC Conclusions Robert W. Harrison, MD Duke Clinical Research Institute Durham, NC Association Between Platelet Aggregation and Mental Stress Induced Myocardial Ischemia: Results From the REMIT Trial Background Objectives Methods Results Variable Normal LV response N=49 MSIMI N=105 P-value Demographics Age, mean (SD), years61.2 (9.4)63.1 (10.9)0.54 Gender (Female)2 (4.1)19 (18.1)0.02 Race (Non-White)5 (10.2)22 (21.0)0.10 Medical History Diabetes16 (32.7)28 (26.7)0.44 Current Angina10 (20.4)22 (21.0)0.95 Prior Myocardial Infarction15 (30.6)53 (50.5)0.07 Prior PCI28 (57.1)65 (61.9)0.57 Prior CABG22 (44.9)52 (49.5)0.59 Congestive Heart Failure1 (2.0)7 (6.67)0.23 Hypertension38 (77.6)79 (75.2)0.75 Hyperlipidemia47 (95.9)97 (92.4)0.41 Current Tobacco Use4 (8.2)19 (18.1)0.27 Depression5 (10.2)19 (18.1)0.21 Baseline Ejection Fraction, mean (SD), % 55.5 (8.7)53.3 (11.0)0.21 Medications Aspirin47 (95.9)102 (98.1)0.44 Additional Antiplatelet20 (40.8)49 (47.1)0.47 ACE-I35 (71.4)69 (66.4)0.53 ARB3 (6.1)16 (15.4)0.11 Calcium Channel Blocker9 (18.8)18 (17.3)0.83 Beta blocker38 (77.6)93 (89.4)0.051 Statin46 (93.9)99 (95.2)0.73 Table 1: Baseline characteristics Agonist Normal LV response N=49 Mean (SD) MSIMI N=105 Mean (SD) P-value Area Under the Curve (% x minutes) ADP 5 µM239.1 (127.5)237.5 (110.0)0.94 Epinephrine, 10 µM147.1 (146.0)139.5 (81.8)0.73 Collagen, 10 µM273.1 (102.1)278.6 (95.6)0.75 Serotonin, 5 µM+ ADP, 1 µM211.7 (119.0)206.0 (105.0)0.77 Serotonin, 5 µM+ Epinephrine, 2 µM243.9 (97.3)242.3 (89.7)0.92 Serotonin, 5 µM + Collagen, 2 µM232.1 (107.4)235.9 (91.3)0.83 Maximal Amplitude (%) ADP 5 µM53.6 (22.4)52.5 (20.7)0.77 Epinephrine, 10 µM28.5 (18.0)29.6 (15.8)0.71 Collagen, 10 µM67.0 (23.1)66.7 (19.6)0.93 Serotonin, 5 µM+ ADP, 1 µM50.0 (20.7)47.9 (18.7)0.53 Serotonin, 5 µM+ Epinephrine, 2 µM53.6 (18.3)52.5 (18.1)0.73 Serotonin, 5 µM + Collagen, 2 µM52.0 (23.4)52.9 (19.9)0.83 Table 2: Baseline resting platelet aggregation Figure: Adjusted change in platelet aggregation following mental stress Data are presented as least squares mean and standard error of the mean after adjustment for gender, baseline EF, and baseline platelet aggregation. *= P < 0.05 MSIMI vs. NLVR * * * * * * * Patients with coronary heart disease are susceptible to mental stress-induced myocardial ischemia (MSIMI), and patients susceptible to MSIMI have a poorer prognosis 1 MSIMI was more common than exercise induced myocardial ischemia in the REMIT trial, affecting 43% of patients with coronary heart disease 2 Patients with MSIMI have a poorer prognosis than those who do not exhibit MSIMI 1 Platelet activation is an important factor in acute coronary syndromes, and patients with depression and hostility have increased platelet reactivity. However, an association between platelet reactivity and MSIMI has not been established 1 Assess platelet aggregation before and after mental stress testing in patients with known coronary heart disease Hypothesis: Patients who are susceptible to MSIMI will have increased mental stress induced platelet aggregation compared to those without MSIMI REMIT NHLBI sponsored randomized clinical trial designed to assess the efficacy of escitalopram on MSIMI in patients with established coronary artery disease Eligible patients: Adults with clinically stable coronary heart disease (prior stenosis > 70%, or history of myocardial infarction or revascularization) Study Procedure Subjects were administered a series of 3 mental tasks: 1) mental arithmetic, 2) public speaking with anger recall, and 3) mirror tracing Blood samples were collected before and after mental stress testing to assess platelet aggregation Platelet Aggregation Aggregation determined with a BIO-DATA 4- channel platelet aggregometer. Variables of interest included the area under the platelet aggregation curve (AUC) and the maximal amplitude of platelet aggregation (%) Aggregation triggered by epinephrine (1, 2, 5, an 10 µM), collagen (1, 2, 5, and 10 µM), adenosine diphosphate (ADP; 1, 2, µM), and each agonist with serotonin (5HT; 10 µM) Endpoints: MSIMI: a decrease in EF of ≥ 8% or a new focal wall motion abnormality induced by mental stress testing Normal left ventricular response (NLVR): No change or an increase in EF, and no focal wall motion abnormalities in response to mental stress testing Mental stress testing resulted in increased platelet aggregation, as measured by the AUC and maximal amplitude, in patients who are susceptible to mental stress induced ischemia Future work should investigate whether or not antiplatelet therapy could be protective against mental stress induced myocardial ischemia in susceptible patients Disclosures: Harrison, RW: None Becker, RC: Honoraria; Bristol-Myers Squibb, Sanofi-Aventis, Boehringer Ingelheim. Research Grants; Bristol-Myers Squibb, Bayer Pharmaceuticals, Johns and Johnson, Regado Biosciences, and AstraZeneca Ortel, JL: Honoraria; Boehringer Ingelheim, Instrumentation Laboratories. Research Grants; Pfizer, Eisai, and GSK Kuchibhatla, M: None Boyle, SH: None Samad, Z: None Velazquez, EJ: Honoraria; Novartis. Speaker’s Bureau; Gilead. Research Grants; Abbott-Vascular Wilson, J: None Kuhn, C: None Williams, RB: Ownership/Partnership/Principal; Williams LifeSkills, Inc. O’Connor, CM: Honoraria; Novella, Cardiology Consulting Associates, Amgen. Ownership/Partnership/ Principal; Biscardia LLC. Research Grants; Otsuka, Roche Diagnostics, BG Medicine, Critical Diagnostics, Astellas, Gilead, GE Healthcare, ResMed Jiang, W: None Sponsorship: National Heart, Lung, and Blood Institute grant number RHL Contact References: 1 Jiang, W. et al Responses of mental stress induced myocardial ischemia to escitalopram treatment: Background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial. Am Heart J. 2012; 163: Jiang W, et al. Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. J Am Coll Cardiol. 2013; 61: